Annexon, Inc. (NASDAQ:ANNX) EVP Sells $31,950.00 in Stock

Annexon, Inc. (NASDAQ:ANNX) EVP Ted Yednock sold 4,500 shares of the company’s stock in a transaction on Thursday, September 19th. The shares were sold at an average price of $7.10, for a total transaction of $31,950.00. Following the completion of the sale, the executive vice president now owns 71,365 shares of the company’s stock, valued at approximately $506,691.50. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Ted Yednock also recently made the following trade(s):

• On Thursday, September 5th, Ted Yednock sold 5,500 shares of Annexon stock. The shares were sold at an average price of $5.64, for a total transaction of $31,020.00.
• On Thursday, August 29th, Ted Yednock sold 5,500 shares of Annexon stock. The shares were sold at an average price of $5.95, for a total transaction of $32,725.00.

Annexon Trading Up 0.1 %

ANNX stock opened at $7.03 on Monday. The stock has a 50-day moving average price of $6.05 and a two-hundred day moving average price of $5.58. The stock has a market cap of $649.66 million, a PE ratio of -4.78 and a beta of 1.28. Annexon, Inc. has a 1 year low of $1.57 and a 1 year high of $8.40.

Annexon (NASDAQ:ANNX) last released its earnings results on Monday, August 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.23). On average, analysts forecast that Annexon, Inc. will post -0.97 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Annexon

Several hedge funds have recently modified their holdings of ANNX. Bain Capital Life Sciences Investors LLC grew its holdings in shares of Annexon by 41.4% in the 4th quarter. Bain Capital Life Sciences Investors LLC now owns 8,061,719 shares of the company’s stock valued at $36,600,000 after acquiring an additional 2,359,793 shares in the last quarter. Lighthouse Investment Partners LLC bought a new position in shares of Annexon in the 4th quarter valued at about $306,000. BVF Inc. IL bought a new position in shares of Annexon in the 4th quarter valued at about $31,780,000. Virtu Financial LLC bought a new position in shares of Annexon in the 4th quarter valued at about $221,000. Finally, Susquehanna Fundamental Investments LLC bought a new position in shares of Annexon in the 1st quarter valued at about $241,000.

Wall Street Analyst Weigh In

A number of research firms recently commented on ANNX. Needham & Company LLC restated a “buy” rating and issued a $16.00 price objective on shares of Annexon in a research report on Tuesday, August 13th. Cantor Fitzgerald restated an “overweight” rating on shares of Annexon in a research report on Monday, September 9th. Finally, HC Wainwright reiterated a “buy” rating and set a $30.00 target price on shares of Annexon in a report on Tuesday, August 13th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Annexon has an average rating of “Buy” and a consensus target price of $15.80.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.